Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Urotronic, Boston Scientific, and Teleflex Battle for Prostate Device Prosperity

Urotronic, Boston Scientific, and Teleflex Battle for Prostate Device Prosperity

24th July 2023

After conducting a clinical trial in which 148 individuals were treated with either a placebo or the new Optilume device, Urotronic received FDA clearance.

The trial used the International Prostate Symptom Score (IPSS), a gauge of symptoms within the lower urinary tract. Outcomes showed these symptoms had diminished to a large extent over the course of a year after using Optilume.

IPSS decreased from 23.4 to 10.9 at the end of a year in the Optilume group, compared to a reduction of just 4.8 in the placebo group. So overall, the placebo was statistically outperformed by the treatment cohort by 7.7 points.

Furthermore, the peak urine flow rate increased twofold from 8.9 mL per second to 19 mL per second at the end of the study, which was likewise associated with the use of Optilume.

Urology professor, Steven Kaplan, explained that “with the highest reported Qmax in BPH [minimally invasive surgical therapy] trials to date, Optilume BPH is the next generation of minimally invasive technology, creating a new drug device space among BPH therapies.”

Similar minimally invasive therapies on the market are the Rezum System, which Boston Scientific obtained for $306 million, and UroLift, which Teleflex acquired from NeoTract for $725 million.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.